MX383462B - Pridopidina para el tratamiento de las discinesias inducidas por fármacos - Google Patents

Pridopidina para el tratamiento de las discinesias inducidas por fármacos

Info

Publication number
MX383462B
MX383462B MX2020002645A MX2020002645A MX383462B MX 383462 B MX383462 B MX 383462B MX 2020002645 A MX2020002645 A MX 2020002645A MX 2020002645 A MX2020002645 A MX 2020002645A MX 383462 B MX383462 B MX 383462B
Authority
MX
Mexico
Prior art keywords
drug
subject
pridopidine
induced
treatment
Prior art date
Application number
MX2020002645A
Other languages
English (en)
Spanish (es)
Other versions
MX2020002645A (es
Inventor
Aric Orbach
Michael Hayden
Michal Geva
Original Assignee
Prilenia Neurotherapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prilenia Neurotherapeutics Ltd filed Critical Prilenia Neurotherapeutics Ltd
Publication of MX2020002645A publication Critical patent/MX2020002645A/es
Publication of MX383462B publication Critical patent/MX383462B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2020002645A 2017-09-08 2018-08-30 Pridopidina para el tratamiento de las discinesias inducidas por fármacos MX383462B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762556314P 2017-09-08 2017-09-08
US201862649184P 2018-03-28 2018-03-28
PCT/US2018/048920 WO2019050775A1 (en) 2017-09-08 2018-08-30 PRIDOPIDINE FOR THE TREATMENT OF DYSKINESIC INDUCED BY A MEDICINAL PRODUCT

Publications (2)

Publication Number Publication Date
MX2020002645A MX2020002645A (es) 2021-06-10
MX383462B true MX383462B (es) 2025-03-14

Family

ID=63684481

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020002645A MX383462B (es) 2017-09-08 2018-08-30 Pridopidina para el tratamiento de las discinesias inducidas por fármacos

Country Status (10)

Country Link
US (2) US20190231768A1 (https=)
EP (1) EP3678664A1 (https=)
JP (1) JP2020533296A (https=)
CN (1) CN111343982A (https=)
AU (1) AU2018329628B2 (https=)
BR (1) BR112020004622A2 (https=)
CA (1) CA3075020C (https=)
IL (1) IL273044A (https=)
MX (1) MX383462B (https=)
WO (1) WO2019050775A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG188298A1 (en) 2010-09-03 2013-04-30 Ivax Int Gmbh Deuterated analogs of pridopidine useful as dopaminergic stabilizers
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
WO2018039475A1 (en) 2016-08-24 2018-03-01 Teva Pharmaceuticals International Gmbh Use of pridopidine for treating dystonias
US12102627B2 (en) 2016-09-16 2024-10-01 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating rett syndrome
EP3920924A4 (en) 2019-02-04 2022-11-16 Prilenia Neurotherapeutics Ltd. LOW-DOSE PRIDOIDIN FOR THE TREATMENT OF PARKINSON'S DISEASE AND OTHER PARKINSONIC-RELATED DISEASES
KR102906269B1 (ko) 2023-08-03 2026-01-02 재단법인대구경북과학기술원 파킨슨 환자의 lid 발병 예측을 위한 정보제공방법

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9904724D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
CA2584831C (en) 2004-10-13 2013-09-17 Neurosearch Sweden Ab Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-n-propyl-piperidine
SE529246C2 (sv) * 2005-10-13 2007-06-12 Neurosearch Sweden Ab Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission
SI2146961T1 (sl) 2007-04-12 2014-08-29 IVAX International GmbH N-oksidni in/ali di-N-oksidni derivati stabilizatorjev/modulatorjev dopaminskega receptorja, ki izkazujejo izboljšane profile kardiovaskularnih stranskih učinkov
US20100197712A1 (en) 2007-06-18 2010-08-05 Arvid Carlsson Use of dopamine stabilizers
US20110206782A1 (en) 2010-02-24 2011-08-25 Auspex Pharmaceuticals, Inc. Piperidine modulators of dopamine receptor
WO2011107583A1 (en) 2010-03-04 2011-09-09 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders
CN103080343A (zh) 2010-07-02 2013-05-01 Skf公司 机械部件和用于表面硬化的方法
SG188298A1 (en) 2010-09-03 2013-04-30 Ivax Int Gmbh Deuterated analogs of pridopidine useful as dopaminergic stabilizers
CN103958469B (zh) 2011-09-07 2016-04-20 梯瓦制药国际有限责任公司 一种新的普利多匹定盐酸盐多晶型形态
MX347209B (es) 2011-12-08 2017-04-19 Teva Pharmaceuticals Int Gmbh La sal de bromhidrato de pridopidina.
HK1206297A1 (en) * 2012-04-04 2016-01-08 Teva Pharmaceuticals International Gmbh Pharmaceutical compositions for combination therapy
PE20160195A1 (es) 2013-06-21 2016-05-14 Teva Pharmaceuticals Int Gmbh Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington
DK177976B8 (en) 2013-07-10 2021-04-22 Jasopels As Apparatus and method for stretching a pelt on a pelt board
PE20161220A1 (es) 2014-01-22 2016-11-23 Teva Pharmaceuticals Int Gmbh Formulaciones de pridopidina de liberacion modificada
KR102166879B1 (ko) 2014-03-10 2020-10-16 어플라이드 머티어리얼스, 인코포레이티드 다중 하전-입자 빔 리소그래피를 위한 픽셀 블렌딩
TW201613859A (en) 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
EP3236964A4 (en) 2014-12-22 2018-09-19 Teva Pharmaceuticals International GmbH L-tartrate salt of pridopidine
EP4282479A3 (en) 2015-02-25 2024-02-21 Prilenia Neurotherapeutics Ltd. Use of pridopidine to treat depression or anxiety
CA2993183A1 (en) 2015-07-22 2017-01-26 Teva Pharmaceuticals International Gmbh Pridopidine base formulations and their use
AR105434A1 (es) 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh Proceso para preparar pridopidina
US11738012B2 (en) 2016-02-24 2023-08-29 Prilenia Neurotherapeutics Ltd. Treatment of neurodegenerative eye disease using pridopidine
ES3025836T3 (en) 2016-08-24 2025-06-09 Prilenia Neurotherapeutics Ltd Use of pridopidine for treating functional decline
WO2018039475A1 (en) 2016-08-24 2018-03-01 Teva Pharmaceuticals International Gmbh Use of pridopidine for treating dystonias
AU2017326436A1 (en) 2016-09-15 2019-04-11 Prilenia Neurotherapeutics Ltd Use of pridopidine for the treatment of anxiety and depression
WO2018053275A1 (en) 2016-09-16 2018-03-22 Teva Pharmaceuticals International Gmbh Use of pridopidine for the treatment of familial dysautonomia
CA3050700C (en) 2017-01-20 2023-10-03 Prilenia Neurotherapeutics Ltd. Use of pridopidine for the treatment of fragile x syndrome
HRP20251431T1 (hr) 2017-08-14 2026-01-02 Prilenia Neurotherapeutics Ltd. Liječenje amiotrofične lateralne skleroze pridopidinom
EP3675830A1 (en) * 2017-08-30 2020-07-08 Prilenia Neurotherapeutics Ltd. High concentration dosage forms of pridopidine
DE102018204527A1 (de) 2017-09-18 2019-03-21 SEs Solutions GmbH Dachhalterung für ein Automobil

Also Published As

Publication number Publication date
US20190231768A1 (en) 2019-08-01
WO2019050775A1 (en) 2019-03-14
CA3075020A1 (en) 2019-03-14
CA3075020C (en) 2021-12-07
US20190350914A1 (en) 2019-11-21
US11000519B2 (en) 2021-05-11
MX2020002645A (es) 2021-06-10
EP3678664A1 (en) 2020-07-15
BR112020004622A2 (pt) 2020-09-24
AU2018329628B2 (en) 2021-04-22
CN111343982A (zh) 2020-06-26
IL273044A (en) 2020-04-30
AU2018329628A1 (en) 2020-04-16
JP2020533296A (ja) 2020-11-19

Similar Documents

Publication Publication Date Title
MX383462B (es) Pridopidina para el tratamiento de las discinesias inducidas por fármacos
BR112019003731A2 (pt) aplicação de pridopidina para tratamento de distonias
MX2017010982A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
CL2020002018A1 (es) Composiciones para modular la expresión de c9orf72. (divisional solicitud 201803582)
DOP2017000271A (es) Métodos de acondicionamiento de pacientes para tratamiento con linfocitos t
MX2015009963A (es) Metodos y composición farmacéutica para el tratamiento y la prevención de cardiomiopatía debido a falta de energía.
MX377141B (es) Composiciones y metodos para modular la expresion de pkk.
EA201890571A1 (ru) Способы и композиции для лечения нарушения, ассоциированного с геном пропротеинконвертазы субтилизин/кексинового типа (pcsk9)
AR086582A1 (es) Anticuerpos anti-kir para el tratamiento de trastornos inflamatorios y autoinmunes
SG10201808063PA (en) Compositions for modulating ataxin 2 expression
CO2021004141A2 (es) Moduladores de la expresión de pnpla3
MX2019007161A (es) Uso de anticuerpos anti-esclerostina en el tratamiento de osteogenesis imperfecta.
CO2019011265A2 (es) Moduladores de la expresión de pcsk9
AR115583A1 (es) Composiciones y métodos para el tratamiento de las enfermedades y trastornos del hígado
EA036102B9 (ru) Терапевтические средства с углевод-опосредованной адресной доставкой
BR112019005040A2 (pt) aplicação de pridopidina para tratamento de síndrome de rett
EA201992248A1 (ru) АНТИ-C5a-АНТИТЕЛА И ИХ ПРИМЕНЕНИЯ
BR112015019564A2 (pt) tratamento de esclerose múltipla com laquinimod
BR112014030279A2 (pt) métodos para tratamento de neutropenia usando agonistas retinóide
EA201792641A1 (ru) Ингибитор оси igfbp3/tmem219 и диабет
UY38506A (es) Composiciones y metodos para tratar y prevenir la esclerosis lateral amiotrofica
MX2022013283A (es) Composiciones para limpieza de colon y tratamiento de trastornos gastrointestinales.
MX2017010654A (es) Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estres.
BR112019000635A2 (pt) inibidor de receptor 2 do tipo toll (tlr2) e seu uso, anticorpo, composição e método para tratar uma afecção inflamatória
CO2021007006A2 (es) Moduladores de la expresión de irf5